Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool.

Antipsychotic Agents / therapeutic use Dyskinesias / drug therapy Humans Movement Disorders / drug therapy Outcome Assessment, Health Care Tardive Dyskinesia / drug therapy Tetrabenazine / therapeutic use
Abnormal involuntary rating scale Antipsychotics Assessment tools Rating scales Tardive dyskinesia

Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
08 2020
Historique:
received: 05 05 2020
revised: 16 06 2020
accepted: 22 06 2020
pubmed: 22 8 2020
medline: 7 9 2021
entrez: 22 8 2020
Statut: ppublish

Résumé

Tardive syndromes (TDS) are a group of hyperkinetic and hypokinetic movement disorders that occurs after exposure to dopamine receptor blocking agents such as antipsychotic and antiemetic drugs. The Abnormal Involuntary Movement Scale (AIMS) is a widely used instrument that has become the standard for assessment of tardive dyskinesia (TDD), the most common form of TDS. However, the AIMS has a number of clinimetric limitations and was designed primarily to assess the anatomic distribution and severity of involuntary movements without regard to phenomenology. To build on recent advances in understanding and treatment of TDS, re-evaluation and revision of the AIMS that could aid both clinical practice and research may be worthwhile. Challenges, such as retaining the efficiency of the current AIMS, incorporating evaluation of impairment in daily activities, and re-training clinicians for a revised examination procedure and rating instrument, are very likely surmountable.

Identifiants

DOI: 10.1016/j.parkreldis.2020.06.023 PMID: 32823151
pubmed: 32823151
pii: S1353-8020(20)30200-5
doi: 10.1016/j.parkreldis.2020.06.023
pii:
doi:

Substances chimiques

Antipsychotic Agents 0
Tetrabenazine Z9O08YRN8O

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-145

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Roongroj Bhidayasiri (R)

Chulalongkorn Center of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand.

John M Kane (JM)

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA.

Karen P Frei (KP)

Loma Linda University Medical Center, Loma Linda, CA, USA.

Stanley N Caroff (SN)

Corporal Michael J. Crescenz VA Medical Center and the University of Pennsylvania Perelman School of Medicine, Philadelphia, USA.

Christoph U Correll (CU)

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA; The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA; The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA; Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany.

Stanley Fahn (S)

Department of Neurology, Columbia University Medical Center, New York, NY, USA.

Joseph Jankovic (J)

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Robert A Hauser (RA)

University of South Florida, Tampa, FL, USA.

Daniel D Truong (DD)

Parkinson's and Movement Disorder Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA; University of California, Riverside, CA, USA. Electronic address: dtruong@pmdi.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Dyskinésies › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Troubles de la motricité › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Dyskinésies › Dyskinésie tardive › Expanding phenomenologic heterogeneity of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinolizines › Tétrabénazine › Expanding phenomenologic heterogeneity of...